Alcon Inc., better known as ACL has received the official approval letter from the United States Food and Drugs Administration, for Extravan ophthalmic solution for the treatment of glaucoma. The solution of Extravan is the fixed combination of Travopost 0.004% and Timolol 0.5%. Alcon develops, manufactures and markets the pharmaceuticals products, surgical equipments and devices, contact lens solutions as well as other vision care products that treat the diseases, disorders or other conditions of the eyes. Extravan is not yet available due to commercially non-approval by the US – FDA.

Alcon is considered as the leading eye care company in the world and it has been devoted to the ophthalmic industry for over 57 years now. Extravan are the eye drops that have Travopost combined with Timolol Maleate 40 micrograms – 5 mg base per milliliter – 0.004% to 5% - 2.5 ml Extravan. The drug is recommended for reducing the raised intra-ocular pressure in the patients with open angle glaucoma or ocular hypertension for whom the single agent therapy for providing inadequate intraocular pressure reduction.    

Extravan is reported to have reduced intraocular pressure from 1.7 mmHg t0 2.4 mmHg which is more than Travopost 0.004% alone at 0800 hours time point in one of the studies. Again at 1000 and 1600 hours time points, Extravan is reported to have decreased IOP between 1 and 2 mmHg which is more than Travopost 0.004% alone. Extravan IOP lowering effects to related therapy, comprising of Travopost 0.004% dosage in the evening and Timolol 0.5% dosage in the morning during a couple of other phase 3 studies, Extravan was statistically equivalent to related therapy at all the 0800 hours time points but was not statistically equivalent at the 1000 and 1600 hours time points. The 0800 hours time point is usually regarded as the most important time point for the IPO controls.